Analysts Anticipate 14% Upside For VIOO
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 24 2025
0mins
Source: NASDAQ.COM
ETF Analysis: The Vanguard S&P Small-Cap 600 ETF (VIOO) has an implied analyst target price of $120.60, indicating a potential upside of 14.06% from its current trading price of $105.73.
Individual Stock Upside: Notable underlying holdings such as Xencor, Enovis Corp, and Corcept Therapeutics show significant upside potential, with target prices suggesting increases of 224.87%, 103.25%, and 102.15% respectively from their recent trading prices.
Analyst Views on XNCR
Wall Street analysts forecast XNCR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XNCR is 27.50 USD with a low forecast of 18.00 USD and a high forecast of 42.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
10 Buy
1 Hold
0 Sell
Strong Buy
Current: 13.000
Low
18.00
Averages
27.50
High
42.00
Current: 13.000
Low
18.00
Averages
27.50
High
42.00
About XNCR
Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
